BR112019023979A2 - compostos, composições e métodos - Google Patents
compostos, composições e métodos Download PDFInfo
- Publication number
- BR112019023979A2 BR112019023979A2 BR112019023979A BR112019023979A BR112019023979A2 BR 112019023979 A2 BR112019023979 A2 BR 112019023979A2 BR 112019023979 A BR112019023979 A BR 112019023979A BR 112019023979 A BR112019023979 A BR 112019023979A BR 112019023979 A2 BR112019023979 A2 BR 112019023979A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- compounds
- inflammation
- preventing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762507682P | 2017-05-17 | 2017-05-17 | |
| PCT/US2018/033269 WO2018213634A1 (en) | 2017-05-17 | 2018-05-17 | Compounds, compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023979A2 true BR112019023979A2 (pt) | 2020-06-09 |
Family
ID=64274734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023979A BR112019023979A2 (pt) | 2017-05-17 | 2018-05-17 | compostos, composições e métodos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11174262B2 (enExample) |
| EP (1) | EP3625234B1 (enExample) |
| JP (2) | JP7140781B2 (enExample) |
| KR (1) | KR102637541B1 (enExample) |
| CN (1) | CN110914275A (enExample) |
| AU (2) | AU2018269745C1 (enExample) |
| BR (1) | BR112019023979A2 (enExample) |
| CA (1) | CA3063938A1 (enExample) |
| IL (1) | IL270505B2 (enExample) |
| MX (1) | MX2019013642A (enExample) |
| WO (1) | WO2018213634A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3552017T (lt) * | 2016-12-09 | 2022-05-10 | Denali Therapeutics Inc. | Junginiai, naudotini kaip ripk1 inhibitoriai |
| CA3063938A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| PL3984523T3 (pl) | 2018-12-07 | 2026-02-02 | Neurocrine Biosciences, Inc. | Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy |
| ES3039926T3 (en) | 2019-12-04 | 2025-10-27 | Neurocrine Biosciences Inc | Crf receptor antagonists and methods of use |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| US20240425524A1 (en) * | 2021-10-27 | 2024-12-26 | Merck Sharp & Dohme Llc | Spirotricycle ripk1 inhibitors and methods of uses thereof |
| CN121986105A (zh) * | 2023-08-31 | 2026-05-05 | 杭州百诚医药科技股份有限公司 | 苯并氮杂䓬酮类化合物及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4290952A (en) * | 1980-06-23 | 1981-09-22 | American Home Products Corporation | Aryl-1-mercaptoalkanoylproline and homoproline derivatives |
| US4320057A (en) * | 1980-06-23 | 1982-03-16 | American Home Products Corporation | Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones |
| BRPI0506883A (pt) * | 2004-01-16 | 2007-05-29 | Univ Michigan | miméticos de smac conformacionalmente comprimidos e seus usos |
| BRPI0513310A (pt) * | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | análogos de tetrapeptìdeo |
| AU2006255084A1 (en) * | 2005-06-08 | 2006-12-14 | Novartis Ag | Organic compounds |
| TWI370130B (en) * | 2005-11-24 | 2012-08-11 | Eisai R&D Man Co Ltd | Two cyclic cinnamide compound |
| MX2009000824A (es) | 2006-07-24 | 2009-02-04 | Tetralogic Pharmaceuticals Cor | Antagonistas dimericos de las proteinas inhibidoras de la apoptosis. |
| WO2014066435A1 (en) | 2012-10-22 | 2014-05-01 | City Of Hope | Etp derivatives |
| US20150023913A1 (en) * | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| WO2016094846A1 (en) | 2014-12-11 | 2016-06-16 | President And Fellows Of Harvard College | Inhibitors of cellular necrosis and related methods |
| WO2016101887A1 (en) * | 2014-12-24 | 2016-06-30 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| CA3063938A1 (en) * | 2017-05-17 | 2018-11-22 | Denali Therapeutics Inc. | Compounds, compositions and methods |
-
2018
- 2018-05-17 CA CA3063938A patent/CA3063938A1/en active Pending
- 2018-05-17 AU AU2018269745A patent/AU2018269745C1/en not_active Ceased
- 2018-05-17 MX MX2019013642A patent/MX2019013642A/es unknown
- 2018-05-17 WO PCT/US2018/033269 patent/WO2018213634A1/en not_active Ceased
- 2018-05-17 EP EP18803112.4A patent/EP3625234B1/en active Active
- 2018-05-17 KR KR1020197036801A patent/KR102637541B1/ko active Active
- 2018-05-17 BR BR112019023979A patent/BR112019023979A2/pt active Search and Examination
- 2018-05-17 CN CN201880047315.8A patent/CN110914275A/zh active Pending
- 2018-05-17 IL IL270505A patent/IL270505B2/en unknown
- 2018-05-17 JP JP2019563609A patent/JP7140781B2/ja active Active
-
2019
- 2019-11-14 US US16/683,970 patent/US11174262B2/en active Active
-
2021
- 2021-10-05 US US17/494,336 patent/US11851433B2/en active Active
-
2022
- 2022-04-14 AU AU2022202524A patent/AU2022202524B2/en not_active Ceased
- 2022-09-07 JP JP2022141824A patent/JP2022174180A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3625234A4 (en) | 2021-03-10 |
| EP3625234A1 (en) | 2020-03-25 |
| JP2022174180A (ja) | 2022-11-22 |
| AU2018269745B2 (en) | 2022-01-27 |
| AU2018269745A1 (en) | 2019-11-28 |
| IL270505B2 (en) | 2023-09-01 |
| AU2022202524A1 (en) | 2022-05-12 |
| US11851433B2 (en) | 2023-12-26 |
| US20220024938A1 (en) | 2022-01-27 |
| AU2018269745C1 (en) | 2022-06-09 |
| EP3625234B1 (en) | 2023-09-20 |
| CA3063938A1 (en) | 2018-11-22 |
| KR20200006120A (ko) | 2020-01-17 |
| MX2019013642A (es) | 2020-07-20 |
| KR102637541B1 (ko) | 2024-02-15 |
| JP2020520925A (ja) | 2020-07-16 |
| US20200079784A1 (en) | 2020-03-12 |
| AU2022202524B2 (en) | 2023-10-05 |
| WO2018213634A1 (en) | 2018-11-22 |
| US11174262B2 (en) | 2021-11-16 |
| IL270505B1 (en) | 2023-05-01 |
| IL270505A (enExample) | 2019-12-31 |
| CN110914275A (zh) | 2020-03-24 |
| JP7140781B2 (ja) | 2022-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018006714A2 (es) | 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa | |
| BR112019018124A2 (pt) | composições e métodos para imunooncologia | |
| BR112018010089A2 (pt) | composições compreendendo cepas bacterianas | |
| BR112017025004A2 (pt) | composições compreendendo cepas bacterianas | |
| MX2022010755A (es) | Inhibidores de quinasa y usos de los mismos. | |
| UY35488A (es) | Xantinas sustituidas y métodos para su uso | |
| BR112018009706A8 (pt) | composições compreendendo cepas bacterianas | |
| BR112018009213A2 (pt) | composições compreendendo cepas bacterianas | |
| BR112017003414A2 (pt) | composições compreendendo caseína e métodos para produzir as mesmas | |
| BR112016008541A2 (pt) | composições úteis para tratar distúrbios relacionados a kit | |
| CU20190006A7 (es) | Composiciones para inhibir masp-3 | |
| MX2021008376A (es) | Cultivo, produccion, procesamiento y uso de cannabis de especialidad. | |
| EA201992177A1 (ru) | Композиции на основе нирапариба | |
| CL2016000221A1 (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| EA201691194A1 (ru) | Стимуляторы ргц | |
| MX2019013642A (es) | Compuestos, composiciones y metodos. | |
| UY35424A (es) | Xantinas sustituidas y métodos para su uso | |
| CL2017002694A1 (es) | Métodos para mejora hidráulica de cultivos | |
| MX2015016585A (es) | Una composicion para aplicacion topica que comprende glicerol y taninos. | |
| BR112018002983A2 (pt) | composição compreendendo uma lactama e um álcool | |
| BR112018000187A2 (pt) | composto, composição, método, e, uso de um composto ou composição | |
| MX395699B (es) | Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas. | |
| MX386158B (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos | |
| BR112017013770A2 (pt) | composições de inibidor de nitrificação microencapsuladas | |
| MX384768B (es) | Composiciones aglomerantes y metodos para fabricacion y uso de las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 487/10 , C07D 495/14 , C07D 495/20 Ipc: C07D 487/10 (2006.01), C07D 495/14 (2006.01), C07D |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |